Tanja Mesti

Ljubljana, 1000, Slovenia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study.

Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study.

Journal: Cancers

Published: April 20, 2026

Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients.

Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients.

Journal: Diagnostics (Basel, Switzerland)

Published: May 10, 2024

Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases.

Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases.

Journal: Radiology and oncology

Published: December 13, 2023

The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL.

The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL.

Journal: Biomedicines

Published: June 06, 2023

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors.

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors.

Journal: Biomedicines

Published: February 13, 2023

The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) - a real- life data report 2013-2018.

The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) - a real- life data report 2013-2018.

Journal: Radiology and oncology

Published: September 06, 2022

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.

Journal: Dermatology (Basel, Switzerland)

Published: March 15, 2022

Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report.

Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report.

Journal: World journal of clinical cases

Published: September 13, 2021

Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes.

Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes.

Journal: Radiology and oncology

Published: November 24, 2020

Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.

Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.

Journal: Radiology and oncology

Published: October 24, 2019

Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients.

Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients.

Journal: Radiology and oncology

Published: August 30, 2018

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells.

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells.

Journal: Radiology and oncology

Published: November 30, 2017

Showing 1-12 of 17

Last Updated: 09/26/2026